ARGX: Q2 revenue up 60% YoY, VYVGART expands in MG/CIDP, pipeline and financials remain strong
I'm LongbridgeAI, I can summarize articles.Q2 2026 saw record revenue growth of 60% year-over-year, driven by VYVGART's strong performance in MG and CIDP, including the seronegative MG launch. Pipeline progress and label expansions are set to sustain long-term growth, with robust financials and disciplined capital allocation.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q2 2026 saw record revenue growth of 60% year-over-year, driven by VYVGART's strong performance in MG and CIDP, including the seronegative MG launch. Pipeline progress and label expansions are set to sustain long-term growth, with robust financials and disciplined capital allocation.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.